Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 16971205)

1.
2.

[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].

Abbrederis K, Kremer M, Schuhmacher C.

Chirurg. 2008 Apr;79(4):351-5. German.

PMID:
17453167
3.

Gastrointestinal perforation due to bevacizumab in colorectal cancer.

Saif MW, Elfiky A, Salem RR.

Ann Surg Oncol. 2007 Jun;14(6):1860-9. Epub 2007 Mar 14. Review.

PMID:
17356952
4.

Endoscopic management of colonic perforation owing to angiogenesis inhibitors.

Ezzedine S, Bege T, Berdah S, Vitton V, Grimaud JC, Barthet M.

Surg Laparosc Endosc Percutan Tech. 2010 Dec;20(6):e230-2. doi: 10.1097/SLE.0b013e318200a115.

PMID:
21150409
5.

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM.

Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10.

PMID:
20382413
6.

[A bowel perforation with metallic stent placement for advanced rectal cancer during bevacizumab-based chemotherapy].

Yoshinami T, Ichiba M, Hayashi S, Yamamoto K, Shibuya M, Higashimoto Y.

Nihon Shokakibyo Gakkai Zasshi. 2010 Apr;107(4):625-31. Japanese.

PMID:
20379097
7.

"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.

August DA, Serrano D, Poplin E.

J Surg Oncol. 2008 Feb 1;97(2):180-5.

PMID:
18095268
8.

[Surgical management of bevacizumab-associated peritonitis due to perforation].

Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H.

Zentralbl Chir. 2009 Sep;134(5):462-7. doi: 10.1055/s-0028-1098701. Epub 2009 Sep 15. German.

PMID:
19757347
9.

Bowel perforation in non-small cell lung cancer after bevacizumab therapy.

Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U.

Invest New Drugs. 2009 Apr;27(2):184-7. doi: 10.1007/s10637-008-9162-z. Epub 2008 Jul 30.

PMID:
18665327
10.

Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.

Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR.

Curr Oncol Rep. 2012 Aug;14(4):277-84. doi: 10.1007/s11912-012-0238-8. Review.

PMID:
22532266
11.

Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer.

Huang GC, Chen LJ, Liu HC, Chen YJ.

Clin Drug Investig. 2008;28(8):523-6. Erratum in: Clin Drug Investig. 2008;28(11):739.

PMID:
18598098
12.

Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.

Liu SV, Gollard R, Iqbal S.

J Clin Pharm Ther. 2012 Oct;37(5):607-9. doi: 10.1111/j.1365-2710.2012.01343.x. Epub 2012 Mar 20.

PMID:
22432770
13.

Managing patients treated with bevacizumab combination therapy.

Gordon MS, Cunningham D.

Oncology. 2005;69 Suppl 3:25-33. Epub 2005 Nov 21. Review.

PMID:
16301833
14.

Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.

Koukourakis MI, Giatromanolaki A, Tsoutsou P, Lyratzopoulos N, Pitiakoudis M, Kouklakis G, Chloropoulou PA, Manolas K, Sivridis E.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):492-8. doi: 10.1016/j.ijrobp.2010.02.037. Epub 2010 Jun 30.

PMID:
20584585
15.

[Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].

Takano M, Kikuchi Y, Kato M, Yoshikawa T, Kita T.

Gan To Kagaku Ryoho. 2008 Nov;35(11):1981-4. Japanese.

PMID:
19011357
16.

Infusion of bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated.

Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R.

Updates Surg. 2013 Jun;65(2):121-4. doi: 10.1007/s13304-013-0207-2. Epub 2013 Mar 27.

PMID:
23532741
17.

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.

Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ.

Invest New Drugs. 2008 Aug;26(4):393-7. doi: 10.1007/s10637-008-9125-4. Epub 2008 Mar 12.

18.

Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.

Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R.

Med Oncol. 2010 Sep;27(3):585-91. doi: 10.1007/s12032-009-9253-5. Epub 2009 Jun 13. Review.

PMID:
19526201
19.

Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

Badgwell BD, Camp ER, Feig B, Wolff RA, Eng C, Ellis LM, Cormier JN.

Ann Oncol. 2008 Mar;19(3):577-82. Epub 2007 Nov 16. Review.

20.

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.

Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick JE 4th, Straughn JM Jr.

Gynecol Oncol. 2009 Sep;114(3):424-6. doi: 10.1016/j.ygyno.2009.05.031. Epub 2009 Jun 23.

PMID:
19552944
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk